Title:
ESTROGEN RECEPTOR ANTAGONIST
Document Type and Number:
WIPO Patent Application WO/2020/125640
Kind Code:
A1
Abstract:
Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.
More Like This:
Inventors:
DUAN SHUWEN (CN)
LU JIANYU (CN)
HU LIHONG (CN)
DING CHARLES Z (CN)
HU GUOPING (CN)
LI JIAN (CN)
CHEN SHUHUI (CN)
LU JIANYU (CN)
HU LIHONG (CN)
DING CHARLES Z (CN)
HU GUOPING (CN)
LI JIAN (CN)
CHEN SHUHUI (CN)
Application Number:
PCT/CN2019/126046
Publication Date:
June 25, 2020
Filing Date:
December 17, 2019
Export Citation:
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN)
MEDSHINE DISCOVERY INC (CN)
MEDSHINE DISCOVERY INC (CN)
International Classes:
C07D209/08; A61P35/00; C07D221/02
Domestic Patent References:
WO2018098251A1 | 2018-05-31 | |||
WO2016196342A1 | 2016-12-08 |
Foreign References:
CN107847498A | 2018-03-27 | |||
CN103189361A | 2013-07-03 | |||
CN104220426A | 2014-12-17 | |||
US20160347717A1 | 2016-12-01 |
Other References:
See also references of EP 3889133A4
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF:
Previous Patent: GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES
Next Patent: ILLUMINATING LIGHTING FIXTURE
Next Patent: ILLUMINATING LIGHTING FIXTURE